Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications

Kidney International

Volumn 55, Issue 2, 1999, Pages 389-399

  Miyata, Toshio ^a,b,c   Van Ypersele De Strihou, Charles ^a,b,c   Kurokawa, Kiyoshi ^a,b,c   Baynes, John W ^a,b,c  

^a University of Tokyo   (Japan)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation end product; Atherosclerosis; Chronic renal failure; Dialysis related amyloidosis; Glycoxidation; Uremic toxicity

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2 ISOPROPYLIDENEHYDRAZONO 4 OXO THIAZOLIDIN 4 YLACETANILIDE; ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; CARBONYL DERIVATIVE; GLUTATHIONE; THIAZOLIDINE DERIVATIVE; THIOCTIC ACID; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; CHRONIC KIDNEY FAILURE; DETOXIFICATION; DIALYSIS; DRUG MECHANISM; HUMAN; LIPID OXIDATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; UREMIA;

EID: 0032910949     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00302.x     Document Type: Article

References (90)

1. 1. BAYNES JW: Perspectives in diabetes: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
2. 2. ARAKI N, UENO N, CHAKRABARTI B, MORINO Y, HORIUCHI S: Immunohistochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem 267:10211-10214, 1992
3. 3. ODETTI P, FORGARTY J, SELL DR, MONNIER VM: Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41:153-159, 1992
4. 4. MAKITA Z, RADOFF S, RAYFIELD EJ, YANG Z, SKOLNIK E, DELANEY V, FRIEDMAN EA: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
5. 5. DYER DG, DUNN JA, THORPE SR, BAILIE KE, LYONS TJ, MCCANCE DR, BAYNES JW: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463-2469, 1993
6. 6. SELL DR, LAPOLLA A, ODETTI P, FORGARTY J, MONNIER VM: Pentosidine formation in skin correlates with severity of complication in individuals with long standing IDDM. Diabetes 41:1286-1292, 1992
7. 7. MCCANCE DR, DYER DG, DUNN JA, DUNN JA, BAILIE KE, THORPE SR, BAYNES JW, LYONS TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91:2470-2478, 1993
8. 8. BERG TJ, BANGSTAND H-J, TORJESEN PA, OSTERBY R, BUCALA R, HANSSEN KF: Advanced glycation end products (AGEs) in serum predict changes in the kidney morphology of IDDM patients. Metabolism 46:661-665, 1997
9. 9. WESTWOOD ME, THORNALLEY PJ: Glycation and advanced glycation end products, in The Glycation Hypothesis of Atherosclerosis, edited by Colaco C, London, Landes Biosciences, 1997, pp 576-587
10. 10. MAKITA Z, VLASSARA H, CERAMI A, BUCALA R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
11. 11. SELL DR, MONNIER VM: Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 264:21597-21602, 1989
12. 12. AHMED MU, THORPE SR, BAYNES JW: Identification of N∈-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261:4889-4894, 1986
13. 13. UCHIDA K, KHOR OT, OYA T, OSAWA T, YASAUDA Y, MIYATA T: Protein modification by a Maillard reaction intermediate methylglyoxal immunochemical detection of fluorescent 5-methylimidazolone derivatives in vivo. FEBS Lett 410:313-318, 1997
14. 14. MIYATA T, UEDA Y, SHINZATO T, IIDA Y, TANAKA S, KUROKAWA K, VAN YPERSELE DE STRIHOU C, MAEDA K: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198-1206, 1996
15. 15. DEGENHARDT TP, GRASS L, REDDY S, THORPE SR, DIAMANDIS EP, BAYNES JW: The serum concentration of the advanced glycation end-product N∈-(carboxymethyl) lysine is increased in uremia. Kidney Int 52:1064-1067, 1997
16. 16. SELL DR, MONNIER VM: End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85:380-384, 1990
17. 17. MIYATA T, Fu MX, KUROKAWA K, VAN YPERSELE DE STRIHOU C, THORPE SR, BAYNES JW: Products of autoxidation of both carbohydrates and lipids are increased in uremic plasma: Evidence for a generalized increase in oxidative stress in uremia? Kidney Int 54:1290-1295, 1998
18. 18. DYER DG, BLACKLEDGE JA, THORPE SR, BAYNES JW: Formation of pentosidine during nonenzymatic browning of protein by glucose: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654-11660, 1991
19. 19. DUNN JA, AHMED MU, MURTIASHAW MH, RICHARDSON JM, WALLA MD, BAYNES JW: Reaction of ascorbate with lysine and protein under autoxidizing conditions: Formation of N∈-(carboxymethyl) lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 29:10964-10970, 1990
20. 20. GRANDHEE SK, MONNIER VM: Mechanism of formation of the Maillard protein cross-link pentosidine. J Biol Chem 266:11649-11653, 1991
21. 21. MIYATA T, WADA Y, CAI Z, IIDA Y, HORIE K, YASUDA Y, MAEDA K, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51:1170-1181, 1997
22. 22. MAKITA Z, BUCALA R, RAYFIELD EJ, FRIEDMAN EA, KAUFMAN AM, KORBET SM, BARTH RH, WINSTON JA, FUH H, MANOGUE KR, CERAMI A, VLASSARA H: Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522, 1994
23. 23. FRIEDLANDER MA, WU YC, ELGAWISH A, MONNIER VM: Early and advanced glycosylation end products. J Clin Invest 97:728-735, 1996
24. 24. MIYATA T, UEDA Y, YOSHIDA A, SUGIYAMA S, IIDA Y, JADOUL M, MAEDA K, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 51:880-887, 1997
25. 25. FU MX, REQUENA JR, JENKINS AJ, LYONS TJ, BAYNES JW, THORPE SR: The advanced glycation end product, N∈-(carboxymethyl) lysine, is a product of lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-9986, 1996
26. 26. ANDERSON MM, HAZEN SL, HSU FF, HEINECKE JW: Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanol, and acrolein: A mechanism for the generation of highly reactive α-hydroxy and α, β-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 99:424-432, 1997
27. 27. MIYATA T, UEDA Y, YASUDA Y, IZUHARA Y, SAITO A, JADOUL M, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol 9:2349-2356, 1998
28. 28. BROWNLEE M, VLASSARA H, KOONEY A, ULRICH P, CERAMI A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
29. 29. NAKAMURA S, MAKITA Z, ISHIKAWA S, YASUMURA K, FUJII W, YANAGISAWA K, KAWATA T, KOIKE T: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:895-899, 1997
30. 30. LYNCH CL, LIM CK, THOMAS M, PETERS TJ: Assay of blood and tissue aldehydes by HPLC analysis of their 2,4-dinitrophenylhydrazine adducts. Clin Chim Acta 130:117-122, 1983
31. 31. WELLS-KNECHT MC, LYONS TJ, MCCANCE DR, THORPE SR, BAYNES JW: Age-dependent increase in ortho-Tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes: Evidence against a generalized increase in oxidative stress in diabetes. J Clin Invest 100:839-846, 1997
32. 32. MIYATA T, MAEDA K, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 12:255-258, 1997
33. 33. CANESTRARI F, GALLI F, GIORGINI A, ALBERTINI MC, GALIOTTA P, PASCUCCI M, BOSSU M: Erythrocyte redox state in uremic anemia: Effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 91:187-193, 1994
34. 34. KUMANO K, YOKOTA S, GO M, SUYAMA K, SAKAI T, ERA S, SOGAMI M: Quantitative and qualitative changes of serum albumin in CAPD patients. Adv Perit Dial 8:127-130, 1992
35. 35. WITKO-SARSAT V, FRIEDLANDER M, CAPEILLERE-BLANDIN C, NGUYEN-KHOA T, NGUYEN AN, ZINGRAFF J, JUNGERS P, DESCAMPS-LATSCHA B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996
36. 36. ODETTI P, GARIBALDI S, GURRERI G, ARAGNO I, DAPINO D, PRONZATO MA: Protein oxidation in hemodialysis and kidney transplantation. Metabolism 45:1319-1322, 1996
37. 37. YEUNG JH: Effects of glycerol-induced acute renal failure on tissue glutathione and glutathione-dependent enzymes in the rat. Methods Find Exp Clin Pharmacol 13:23-28, 1991
38. 38. DASGUPTA A, HUSSAIN S, AHMAD S: Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 60:56-59, 1992
39. 39. ROSELAAR SE, NAZHAT NB, WINYARD PG, JONES P, CUNNINGHAM J, BLAKE DR: Detection of oxidant in uremic plasma by electron spin resonance spectroscopy. Kidney Int 48:199-206, 1995
40. 40. WELLS-KNECHT KJ, ZYZAK DV, LITCHFIELD JE, THORPE SR, BAYNES JW: Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of protein by glucose. Biochemistry 34:3702-3709, 1995
41. 41. AHMED MA, FRYE EB, THORPE SR, BAYNES JW: N∈-(carboxymethyl) lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 324:565-570, 1997
42. 42. GLOMB MA, MONNIER VM: Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 276:10017-10025, 1995
43. 43. ESTERBAUER H, SCHUER RJ, ZOLLNER H: Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehyde. Free Radic Biol Med 11:81-128, 1991
44. 44. UCHIDA K, KANEMATSU M, SAKAI K, MATSUDA T, HATTORI N, SUZUKI D, MIYATA T, NOGUCHI N, NIKI E, OSAWA T: Protein-bound acrolein: Potential markers for oxidative stress. Proc Natl Acad Sci USA 95:4882-4887, 1998
45. 45. LAL S, SZWERGOLD BS, TAYLOR AH, RANDALL WC, KAPPLER F, WELLS-KNECHT KJ, BAYNES JW, BROWN TR: Metabolism of fructose-3-phosphate in the diabetic rat lens. Arch Biochem Biophys 318:191-199, 1995
46. 46. HAYASHI T, NAMIKI M: Role of sugar fragmentation in the Maillard reaction, in Amino-Carbonyl Reaction in Food and Biological Systems, edited by Fujimaki M, Namiki M, Kato H, Amsterdam, Elsevier, 1986, pp 29-38
47. 47. MLAKAR A, SPITELLER G: Reinvestigation of lipid peroxidation of linolenic acid. Biochim Biophys Acta 1214:209-220, 1994
48. 48. THORNALLEY PJ: Advanced glycation and development of diabetic complications: Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 3:149-166, 1996
49. 49. NIWA T, KATSUZAKI T, MOMOI T, MIYAZAKI T, OGAWA H, SAITO A, MIYAZAKI S, MAEDA K, TATEMICHI N, TAKEI Y: Modification of β2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 49:861-867, 1996
50. 50. ODANI H. SHINZATO T, USAMI J, MATSUMOTO Y, BRINKMANN FRYE E, BAYNES HW, MAEDA K: Imadazolium crosslinks derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients: Evidence for increased oxidative stress in uremia. FEBS Lett 427:381-385, 1998
51. 51. WILLIAMSON JR, CHANG K, KHALID MF, KASAN KS, IDO Y, KAWAMURA T, NYENGAARD JR, VAN DEN ENDEN M, KILO C, TILTON RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813, 1993
52. 52. MIYATA T, MAEDA K: Pathogenesis of dialysis-related amyloidosis. Curr Opin Nephrol Hypertens 4:493-497, 1995
53. 53. MIYATA T, JADOUL M, KUROKAWA K, VAN YPERSELE DE STRIHOU C: β2-Microglobulin in renal disease. J Am Soc Nephrol 9:1723-1735, 1998
54. 54. JADOUL M, GARBAR C, NOEL H, SENNESAEL J, VANHOLDER R, BERNAERT P, RORIVE G, HANIQUE G, VAN YPERSELE DE STRIHOU C: Histological prevalence of β2-microglobulin amyloidosis in haemodialysis: A prospective post-mortem study. Kidney Int 51:1928-1932, 1997
55. 55. OHASHI K, HARA M, KAWAI R, OGURA Y, HONDA K, NIHEI H, MIMURA N: Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int 41:1646-1652, 1992
56. 56. ARGILES A, MOURAD G, KERR PG, GARCIA M, COLLINS B, DEMAILLE JG: Cells surrounding haemodialysis-associated amyloid deposits are mainly macrophages. Nephrol Dial Transplant 9:662-667, 1994
57. 57. GEJYO F, HOMMA N, SUZUKI Y, ARAKAWA M: Serum levels of β2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 314:585-586, 1986
58. 58. LINKE RP, HAMPL H, LOBECK H, RITZ E, BOMMER J, WALDHERR R, EULITZ M: Lysine-specific cleavage of β2-microglobulin in amyloid deposits associated with hemodialysis. Kidney Int 36:675-681, 1989
59. 59. ODANI H, OYAMA R, TITANI K, OGAWA H, SAITO A: Purification and complete amino acid sequence of novel β2-microglobulin. Biochem Biophys Res Commun 168:1223-1229, 1990
60. 60. MIYATA T, ODA O, INAGI R, IIDA Y, ARAKI N, YAMADA N, HORIUCHI S, TANIGUCHI N, MAEDA K, KINOSHITA T: β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243-1252, 1993
61. 61. MIYATA T, TANEDA S, KAWAI R, UEDA Y, HORIUCHI S, HARA M, MAEDA K, MONNIER VM: Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 93:2353-2358, 1996
62. 62. NIWA T, MIYAZAKI S, KATSUZAKI T, TATEMICHI N, TAKEI Y, MIYAZAKI T, MORITA T, HIRASAWA Y: Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 48:771-778, 1995
63. 63. MIYATA T, HORI O, ZHANG JH, YAN SD, FERRAN L, IIDA Y, SCHMIDT AM: The receptor for advanced glycation end products mediates the interaction of AGE-β2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implication for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98:1088-1094, 1997
64. 64. NIWA T, SATO M, KATSUZAKI T, TOMOO T, MIYAZAKI T, TATEMICHI N, TAKEI Y, KONDO T: Amyloid β2-microglobulin is modified with N∈-(carboxymethyl) lysine in dialysis-related amyloidosis. Kidney Int 50:1303-1309, 1996
65. 65. NIWA T, KATSUZAKI T, MIYAZAKI S, MOMOI T, AKIBA T, MIYAZAKI T, NOKURA K, HAYASE F, TATEMICHI N, TAKEI Y: Amyloid β2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 51:187-194, 1997
66. 66. MIYATA T, INAGI R, WADA Y, UEDA Y, IIDA Y, TAKAHASHI M, TANIGUCHI N, MAEDA K: Glycation of human β2-microglobulin in patients with hemodialysis-associated amyloidosis: Identification of the glycated sites. Biochemistry 33:12215-12221, 1994
67. 67. HORIE K, MIYATA T, MAEDA K, MIYATA S, SUGIYAMA S, SAKAI H, VAN YPERSELE DE STRIHOU C, MONNIER VM, WITZTUM JL, KUROKAWA K: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100:2995-3004, 1997
68. 68. STADTMAN ER, OLIVER CN: Metal catalyzed oxidation of proteins: Physiological consequences. J Biol Chem 266:2005-2008, 1991
69. 69. STADTMAN ER: Protein oxidation and aging. Science 257:1220-1224, 1992
70. 70. SMITH MA, PERRY G, RICHEY PL, ANDERSON VE, BEAL MF, KOWALL N: Oxidative damage in Alzheimer's. Nature 382:120-121, 1996
71. 71. KODAMA T, FREEMAN M, ROHRER L, ZABRECHY J, MATSUDAIRA P, KREIGER M: Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coil. Nature 343:531-535, 1990
72. 72. NEEPER M, SCHMIDT AM, BRETT J, YAN SD, WANG F, PAN YC, ELLISTON K, STERN D, SHAW A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of pro-teins. J Biol Chem 267:14998-15004, 1992
73. 73. SCHMIDT AM, YON SD, BRETT J, MORA R, NOWYGROD R, STERN D: Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 92:2155-2168, 1993
74. 74. KIRSTEIN M, BRETT J, RADOFF S, OGAWA S, STERN D, VLASSARA H: Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 87:9010-9014, 1990
75. 75. MIYATA T, INAGI R, IIDA Y, SATO M, YAMADA N, ODA O, MAEDA M, SEO H: Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin-1. J Clin Invest 93:521-528, 1994
76. 76. CAI T, MIYATA T, HORIE K, IIDA Y, MAEDA K: β2-Microglobulin modified with advanced glycation end products induces monocyte chemotaxis in vivo. Nephrol Dial Transplant 11:1189-1191, 1996
77. 77. VLASSARA H, BROWNLEE M, MANOGUE KR, DINARELLO CA, PASAGIAN A: Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 240:1546-1548, 1988
78. 78. IIDA Y, MIYATA T, INAGI R, SUGIYAMA S, MAEDA K: β2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: Role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 201:1235-1241, 1994
79. 79. MIYATA T, SPRAGUE SM: Advanced glycation of β2-microglobulin in the pathogenesis of bone lesions in dialysis associated amyloidosis. Nephrol Dial Transplant 11(Suppl 3):86-90, 1996
80. 80. MIYATA T, NOTOYA K, YOSHIDA K, HORIE K, KUROKAWA K, MAEDA K, TAKETOMI S: Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mousefractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8:260-270, 1997
81. 81. SATOH H, TOGO M, HARA M, MIYATA T, HAN K, MAEKAWA H, OHNO M, HASHIMOTO Y, KUROKAWA K, WATANABE T: Advanced glycation end products stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells. Biochem Biophys Res Commun 239:111-115, 1997
82. 82. BUCALA R, TRACEY KJ, CERAMI A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87:432-438, 1991
83. 83. MIYATA T, IIDA Y, UEDA Y, SHINZATO T, SEO H, MONNIER VM, MAEDA K, WADA Y: Monocyte/macrophage response to β2-microglobulin modified with the advanced glycation end products. Kidney Int 49:538-550, 1996
84. 84. YAN SD, SCHMIDT AM, ANDERSON GM, ZHANG J, BRETT J, Zou YS, PINSKY D, STERN D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
85. 85. LEONARDUZZI G, SCAVAZZA A, BIASI F, CHIARPOTTO E, CAMANDOLA S, VOGL S, POLI G: The lipoxidation end product 4-hydroxy-2,3-nonenal upregulates transforming growth factor β1 expression in macrophage lineage: A link between oxidative injury and fibrosclerosis. FASEB J 11:851-857, 1997
86. 86. RHODES J: Covalent chemical events in immune induction: Fundamental and therapeutic aspects. Immunol Today 9:436-441, 1996
87. 87. PONGOR S, ULRICH PC, BENCSATH FA, CERAMI A: Aging of proteins: Isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci USA 81:2684-2688, 1984
88. 88. NJOROGE FG, SAYRE LM, MONNIER VM: Detection of glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohydr Res 167:211-220, 1987
89. 89. TAKATA K, HORIUCHI S, ARAKI N, SHIGA M, SAITOH M, MORINO Y: Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem 263:14819-14825, 1988
90. 90. FU S, FU MX, BAYNES JW, THORPE SR, DEAN RT: Presence of DOPA and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): Amino acid oxidation products as possible source of oxidative stress induced by AGE-proteins. Biochem J 330:233-239, 1998